Research consistently shows that weight regain commonly occurs after discontinuation of GLP-1 therapy
PMID 24361556
Mazdutide, a dual glucagon and GLP-1 agonist, is approved
Focus on eating enough protein, staying hydrated, exercising regularly, getting adequate sleep, and following your treatment plan consistently
Bioanalytical validation was performed by employing a fully automated flow-through elution method coupled with on-line SPE-LC-ESI-MS/MS for the quantitative determination of four representative opioids (Morphine, Codeine, Oxycodone, Hydrocodone) and five stimulants (Amphetamine, Methamphetamine, 3, 4-Methylenedioxymeth-amphetamine (MDMA), Phentermine, and Mephedrone) in one method using their corresponding deuterium-labeled analogues as internal standards